Coloplast

Multiple silver linings in spite of a soft Q2 24

15/05/24 -"Coloplast reported softer than expected Q2 24 figures. However, with healthy organic growth, the miss reflected FX headwinds, and, hence, was not that worrisome. Importantly, growth was strong across ..."

PDF page sample
Pages
63
Language
English
Published on
15/05/24
Download
You may also be interested by these reports :
10/02/26
Philips’ Q4 results exceeded expectations, with comparable sales growth driven by strong performance in Personal Health and healthy contributions ...
06/02/26
Coloplast delivered a weak Q1, with both revenue and adjusted EBIT missing consensus. Organic growth of 6% was in line with expectations, but ...
06/02/26
Qiagen’s Q4 results surpassed both market expectations and management’s guidance, with most segments reporting gains. The 2026 guidance aligns with ...
05/02/26
GN’s Q4 results fell short of market expectations. While Hearing experienced healthy growth, this was overshadowed by weaknesses in Gaming and ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO